
Kezar Life Sciences (KZR) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Kezar Life Sciences in November 2026.
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Kezar Life Sciences (KZR) Stock Forecast
Analyst price target, next 12 months
$70.67
+888.3% vs today's $7.15
Price range over the last 12 months
Close to its 12-month high
Analysts covering Kezar Life Sciences have a consensus 12-month target of $70.67, above the current price of $7.15.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Kezar Life Sciences' stock with a target price of $70.67, indicating potential growth.
Financial Health
Kezar Life Sciences is showing strong cash flow and solid book value, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.